SciBase Receives First Order in Austria
SciBase Receives First Order in Austria
For additional information, please contact:STOCKHOLM, May 30, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of artificial intelligence (AI)-based solutions for skin disorders, is pleased to announce that it has received the first order for a Nevisense system with electrodes in Austria.
斯德哥爾摩，2024 年 5 月 30 日 /PRNewswire/-- SciBase Holding AB（“SciBase”） （停止：SCIB）是基於人工智能（AI）的皮膚病解決方案的領先開發商，很高興地宣佈，它已在奧地利收到了第一批帶電極的Nevisense系統的訂單。
SciBase has since the end of the first quarter, following the strong development in Germany, expanded into Austria and Switzerland. In March, a sales representative was hired in Austria with previous experience in establishing businesses in dermatology and he is now responsible for establishing Nevisense in these markets. Nevisense has been presented and demonstrated in local congresses in Austria, which now is beginning to yield positive results.
繼德國的強勁發展之後，SciBase自第一季度末以來已擴展到奧地利和瑞士。3月，奧地利聘請了一位銷售代表，該代表以前曾在皮膚科領域建立業務，現在他負責在這些市場建立Nevisense。Nevisense已在奧地利的地方代表大會上進行了展示和演示，現在已開始取得積極成果。
"It is pleasing to see that our strategy and belief in Nevisense is beginning to bear fruit. Joachim Kaiser, our sales representative in Austria, does a fantastic job and has managed to get a first sale in a short time. This strengthens our belief that Austria and Switzerland can develop into good markets for us," says Pia Renaudin CEO of SciBase.
“令人高興的是，我們對Nevisense的戰略和信念開始取得成果。我們在奧地利的銷售代表Joachim Kaiser做得非常出色，並在短時間內成功實現了第一筆銷售。這堅定了我們的信念，即奧地利和瑞士可以爲我們發展成爲良好的市場。” SciBase首席執行官皮亞·雷諾丁說。
For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
欲了解更多信息，請聯繫：
Pia Renaudin，VD，電話 +46732069802，電子郵件：[email protected]
Certified Advisor (CA):
認證顧問 (CA)：
Vator Securities
Tel: +46 8 580 065 99
Email: [email protected]
Vator 證券
電話：+46 8 580 065 99
電子郵件：[電子郵件保護]
About SciBase:
關於 SciBase：
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
SciBase 是一家全球醫療技術公司，專門從事皮膚病學的早期發現和預防。SciBase 開發並商業化了 Nevisense，這是一個獨特的即時護理平台，它結合了人工智能（人工智能）和先進的 EIS 技術，可提高診斷準確性，確保積極的皮膚健康管理。
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
我們的承諾是最大限度地減少患者的痛苦，使臨床醫生能夠通過及時的檢測和干預來改善和挽救生命，並降低醫療成本。
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SciBase建立在瑞典斯德哥爾摩卡羅林斯卡研究所20多年的研究基礎上，是皮膚病學進步領域的領導者。
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at . All press releases and financial reports can be found here:
該公司自2015年6月2日起在納斯達克第一北方成長市場交易所上市。要了解更多，請訪問。所有新聞稿和財務報告都可以在這裏找到：
This information was brought to you by Cision
這些信息是由 Cision 帶給你的
The following files are available for download:
以下文件可供下載：
|
AT first order |
|
第一次下單 |
譯文內容由第三人軟體翻譯。
